Mountain Crest Acquisition II said its S-4 registration statement on the proposed merger with Better Therapeutics has been declared effective by the SEC. The SPAC called an Oct., 27 meeting for shareholders to vote on the deal.
The transaction values the prescription digital therapeutics company at a pro forma fully diluted enterprise value of approximately $187 million with existing Better Therapeutics shareholders rolling over 100 percent of their equity into the combined company. Read more.
